SigRM offers breakthrough in single-cell epitranscriptomics analysis

Researchers have developed a new tool that will help scientists study how genes are expressed in our cells.

Novo Holdings’ acquisition of Catalent gains EC approval

December 9, 2024

BeiGene’s Brukinsa bags fifth FDA approval, likely positioning it for continued sales growth

BeiGene’s Brukinsa has clinched a fifth US green light in B-cell malignancies — this time for follicular lymphoma (FL) — further expanding its reach in

March 8, 2024

Formycon reports audited annual results for the financial year 2023 – Looking back on a successful operative year and exceeded guidance – Biotech Investments

EQS-News: Formycon AG / Key word(s): Annual Report/Forecast Formycon reports audited annual results for the financial year 2023 – Looking back on a successful operative

April 26, 2024

Supercharge Your Portfolio with Future Health Stocks!

Join us for Profitable Insights & Expert Tips!

With expert analysis, comprehensive market coverage, and actionable insights, our newsletter equips you with the knowledge & tools necessary to make informed decisions & maximize your potential returns in the dynamic world of future health stocks.